Use of Breast-Specific PET Scanners and Comparison with MR Imaging

Narayanan, Deepa; Berg, Wendie A.

doi:10.1016/j.mric.2017.12.006

Cited by 12 publications

(14 citation statements)

References 38 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Other studies investigating the value of dedicated breast PET did find clinical usefulness for the evaluation of the extent of disease [ 14 , 15 , 16 ].…”

Section: Discussionmentioning

confidence: 99%

Characterisation of MRI Indeterminate Breast Lesions Using Dedicated Breast PET and Prone FDG PET-CT in Patients with Breast Cancer—A Proof-of-Concept Study

Malhotra

Tincey

Naidu

et al. 2020

JPM

View full text Add to dashboard Cite

Magnetic resonance imaging (MRI) in patients with breast cancer to assess extent of disease or multifocal disease can demonstrate indeterminate lesions requiring second-look ultrasound and ultrasound or MRI-guided biopsies. Prone positron emission tomography-computed tomography (PET-CT) is a dedicated acquisition performed with a breast-supporting device on a standard PET-CT scanner. The MAMmography with Molecular Imaging (MAMMI, Oncovision, Valencia, Spain) PET system (PET-MAMMI) is a true tomographic ring scanner for the breast. We investigated if PET-MAMMI and prone PET-CT were able to characterise these MRI- indeterminate lesions further. A total of 10 patients with breast cancer and indeterminate lesions on breast MRI were included. Patients underwent prone PET-MAMMI and prone PET-CT after injection of FDG subsequently on the same day. Patients then resumed their normal pathway, with the clinicians blinded to the results of the PET-MAMMI and prone PET-CT. Of the MRI-indeterminate lesions, eight were histopathologically proven to be malignant and two were benign. PET-MAMMI and prone PET-CT only were able to demonstrate increased FDG uptake in 1/8 and 0/8 of the MRI-indeterminate malignant lesions, respectively. Of the MRI-indeterminate benign lesions, both PET-MAMMI and prone PET-CT demonstrated avidity in 1/2 of these lesions. Our findings do not support the use of PET-MAMMI to characterise indeterminate breast MRI lesions requiring a second look ultrasound.

show abstract

“…Other studies investigating the value of dedicated breast PET did find clinical usefulness for the evaluation of the extent of disease [ 14 , 15 , 16 ].…”

Section: Discussionmentioning

confidence: 99%

Characterisation of MRI Indeterminate Breast Lesions Using Dedicated Breast PET and Prone FDG PET-CT in Patients with Breast Cancer—A Proof-of-Concept Study

Malhotra

Tincey

Naidu

et al. 2020

JPM

View full text Add to dashboard Cite

show abstract

“…Alternatively, PET/MRI systems are increasingly being utilized for evaluation of disease extent or treatment response in breast cancer [ 66 , 93 ]. Breast-specific PET imaging using positron emission mammography (PEM) or dedicated breast PET systems (dbPET) have also been proposed for breast cancer imaging [ 72 , 94 , 95 , 96 , 97 ]. These typically offer improved PET resolution compared with whole-body PET cameras, may allow imaging in the prone position similar to breast MRI, and allow PET guidance for tissue biopsy [ 66 , 97 ].…”

Section: Breast Cancermentioning

confidence: 99%

PET-CT in Clinical Adult Oncology: II. Primary Thoracic and Breast Malignancies

Covington

Koppula

Fine

et al. 2022

Cancers

View full text Add to dashboard Cite

Positron emission tomography combined with x-ray computed tomography (PET-CT) is an advanced imaging modality with oncologic applications that include staging, therapy assessment, restaging, and surveillance. This six-part series of review articles provides practical information to providers and imaging professionals regarding the best use of PET-CT for the more common adult malignancies. The second article of this series addresses primary thoracic malignancy and breast cancer. For primary thoracic malignancy, the focus will be on lung cancer, malignant pleural mesothelioma, thymoma, and thymic carcinoma, with an emphasis on the use of FDG PET-CT. For breast cancer, the various histologic subtypes will be addressed, and will include 18F fluorodeoxyglucose (FDG), recently Food and Drug Administration (FDA)-approved 18F-fluoroestradiol (FES), and 18F sodium fluoride (NaF). The pitfalls and nuances of PET-CT in breast and primary thoracic malignancies and the imaging features that distinguish between subcategories of these tumors are addressed. This review will serve as a resource for the appropriate roles and limitations of PET-CT in the clinical management of patients with breast and primary thoracic malignancies for healthcare professionals caring for adult patients with these cancers. It also serves as a practical guide for imaging providers, including radiologists, nuclear medicine physicians, and their trainees.

show abstract

“…The predicted NTE P mm ½ (SD) based on the registration and the in-plane component distance error (dIP mm ½ ) and NTE I mm ½ (Section 3.B) was 0.98 AE 0.39 mm [Eq. (8)] which is equivalent to a sampling radius of 1.10 mm (2.20 mm in diameter) [Eq. (5)] with an upper 95% confidence interval.…”

Section: C System Breast Phantom Studymentioning

confidence: 99%

“…5,6 Importantly, PET is independent of breast tissue density and hormonal changes, removing limitations associated with x-ray mammographic methods and contrast-enhanced MRI. 5,7,8 However, whole-body PET has low spatial resolutions and decreased uptake in low-grade lesions, which limit its detectability in small, early-stage breast cancer for tumor sampling. [9][10][11][12][13] Positron emission mammography (PEM) has been developed to address these whole-body limitations.…”

Section: Introductionmentioning

confidence: 99%

“…In combination with 18F‐fluorodeoxyglucose (FDG) radiotracers, PET has proven highly effective for detecting breast cancer, resulting from its increased metabolic activity, characterized by cancerous tissues 5,6 . Importantly, PET is independent of breast tissue density and hormonal changes, removing limitations associated with x‐ray mammographic methods and contrast‐enhanced MRI 5,7,8 . However, whole‐body PET has low spatial resolutions and decreased uptake in low‐grade lesions, which limit its detectability in small, early‐stage breast cancer for tumor sampling 9–13 .…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Development of a mechatronic guidance system for targeted ultrasound‐guided biopsy under high‐resolution positron emission mammography localization

et al. 2021

View full text Add to dashboard Cite

Image-guided needle biopsy of small, detectable lesions is crucial for early-stage diagnosis, treatment planning, and management of breast cancer. High-resolution positron emission mammography (PEM) is a dedicated functional imaging modality that can detect breast cancer independent of breast tissue density, but anatomical context and real-time needle visualization are not yet available to guide biopsy. We propose a mechatronic guidance system integrating an ultrasound (US)-guided core-needle biopsy (CNB) with high-resolution PEM localization to improve the spatial sampling of breast lesions. This paper presents the benchtop testing and phantom studies to evaluate the accuracy of the system and its constituent components for targeted PEM-US-guided biopsy under simulated high-resolution PEM localization. Methods: A mechatronic guidance system was developed to operate with the Radialis PEM system and a conventional US system. The system includes a user-operated guidance arm and end-effector biopsy device, integrating a US transducer and CNB gun, with its needle focused on a remote center of motion (RCM). Custom software modules were developed to track, display, and guide the end-effector biopsy device. Registration of the mechatronic guidance system to a simulated PEM detector plate was performed using a landmark-based method. Testing was performed with fiducials positioned in the peripheral and central regions of the simulated detector plate and registration error was quantified. Breast phantom experiments were performed under ideal detection and localization to evaluate for bias in the end-effector biopsy device. The accuracy of the complete mechatronic guidance system to perform targeted breast biopsy was assessed using breast phantoms with simulated lesions. Three-dimensional positioning error was quantified, and principal component analysis assessed for directional trends in 3D space within 95% prediction intervals. Targeted breast biopsies with test phantoms were performed and an overall in-plane needle targeting error was quantified. Results: The mean registration errors were 0.63 mm (N = 44) and 0.73 mm (N = 72) in the peripheral and central regions of the simulated PEM detector plate, respectively. A 3D 95% prediction ellipsoid shows an error volume <2.0 mm in diameter, centered on the mean registration error. Under ideal detection and localization, targets <1.0 mm in diameter can be sampled with 95% confidence. The complete mechatronic guidance system was able to successfully spatially sample simulated breast lesions, 4 mm and 6 mm in diameter and height (N = 20) in known 3D positions in the PEM image coordinate space. The 3D positioning error was 0.85 mm (N = 20) with 0.64 mm in-plane and 0.44 mm cross-plane component errors. Targeted breast biopsies resulted in a mean in-plane needle targeting error of 1.08 mm (N = 15) allowing for targets 1.32 mm in radius to be sampled with 95% confidence. Conclusions: We demonstrated the utility of our mechatronic guidance system for targeted breast biopsy under high...

show abstract

Use of Breast-Specific PET Scanners and Comparison with MR Imaging

Cited by 12 publications

References 38 publications

Characterisation of MRI Indeterminate Breast Lesions Using Dedicated Breast PET and Prone FDG PET-CT in Patients with Breast Cancer—A Proof-of-Concept Study

Characterisation of MRI Indeterminate Breast Lesions Using Dedicated Breast PET and Prone FDG PET-CT in Patients with Breast Cancer—A Proof-of-Concept Study

PET-CT in Clinical Adult Oncology: II. Primary Thoracic and Breast Malignancies

Development of a mechatronic guidance system for targeted ultrasound‐guided biopsy under high‐resolution positron emission mammography localization

Contact Info

Product

Resources

About